PDF(Pubmed)
Abstract：
UNASSIGNED: The purpose of this study is to evaluate the efficacy of Vitamin A (VitA) as an adjuvant therapy for pediatric Mycoplasma Pneumoniae Pneumonia (MPP) through meta-analysis, and to investigate its impact on inflammation levels (IL-6, IL-10), in order to explore the role of VitA in pediatric MPP.
UNASSIGNED: Using a systematic literature search method, relevant research literature is searched, and RCT studies that meet the requirements are selected based on preset inclusion and exclusion criteria. Then, a quality evaluation was conducted on the included literature, and meta-analysis was used to calculate the combined effect values of mortality rate, hospital stay, lung rale disappearance time, cough duration, fever duration, IL-6 and IL-10 levels, and heterogeneity analysis was conducted. The levels of IL-6 and IL-10 represent the inflammatory levels in pediatric MPP patients, and exploring their changes has significant implications for the anti-inflammatory effect of treatment.
UNASSIGNED: A total of 10 RCT studies were included, with a total sample size of 1,485, including 750 cases in the control group and 735 cases in the observation group. The meta-analysis results of this study showed that there was a significant difference in the total clinical efficacy of using VitA adjuvant therapy compared to the control group without VitA [OR = 3.07, 95%CI = (2.81, 4.27)], P < 0.05. However, there was no significant difference in the adverse reaction rate between the use of VitA as an adjuvant therapy and the control without VitA [OR = 1.17, 95%CI = (0.61, 2.27)], P > 0.05. At the same time, the hospitalization time [MSD = -0.86, 95% CI = (-1.61, -0.21)], lung rale disappearance time [MSD = -0.78, 95%CI = (-1.19,-0.51)], cough duration [MSD = -1.07, 95%CI = (-1.41, -0.71)], and fever duration [MSD = -0.47, 95%CI = (-0.72, -0.23)] using VitA as an adjuvant treatment were obviously lower. In addition, the meta-analysis outcomes also showed that the use of VitA adjuvant therapy can significantly reduce IL-6 [MSD = -1.07, 95%CI = (-1.81, -0.27)] and IL-10 [MSD = -0.13, 95%CI = (-0.31, 0.12)] levels. This indicates that the application of VitA in pediatric MPP also has the effect of reducing inflammatory response.
UNASSIGNED: Based on the meta-analysis results, VitA adjuvant therapy can significantly improve the clinical symptoms of pediatric MPP patients, shorten hospitalization time, promote the disappearance of lung rales, and alleviate cough and fever symptoms. In addition, VitA adjuvant therapy can effectively reduce inflammation levels, indicating its potential role in inhibiting inflammatory responses. In clinical practice, VitA adjuvant therapy for pediatric MPP can be promoted as a potential treatment option.
UNASSIGNED: Using a systematic literature search method, relevant research literature is searched, and RCT studies that meet the requirements are selected based on preset inclusion and exclusion criteria. Then, a quality evaluation was conducted on the included literature, and meta-analysis was used to calculate the combined effect values of mortality rate, hospital stay, lung rale disappearance time, cough duration, fever duration, IL-6 and IL-10 levels, and heterogeneity analysis was conducted. The levels of IL-6 and IL-10 represent the inflammatory levels in pediatric MPP patients, and exploring their changes has significant implications for the anti-inflammatory effect of treatment.
UNASSIGNED: A total of 10 RCT studies were included, with a total sample size of 1,485, including 750 cases in the control group and 735 cases in the observation group. The meta-analysis results of this study showed that there was a significant difference in the total clinical efficacy of using VitA adjuvant therapy compared to the control group without VitA [OR = 3.07, 95%CI = (2.81, 4.27)], P < 0.05. However, there was no significant difference in the adverse reaction rate between the use of VitA as an adjuvant therapy and the control without VitA [OR = 1.17, 95%CI = (0.61, 2.27)], P > 0.05. At the same time, the hospitalization time [MSD = -0.86, 95% CI = (-1.61, -0.21)], lung rale disappearance time [MSD = -0.78, 95%CI = (-1.19,-0.51)], cough duration [MSD = -1.07, 95%CI = (-1.41, -0.71)], and fever duration [MSD = -0.47, 95%CI = (-0.72, -0.23)] using VitA as an adjuvant treatment were obviously lower. In addition, the meta-analysis outcomes also showed that the use of VitA adjuvant therapy can significantly reduce IL-6 [MSD = -1.07, 95%CI = (-1.81, -0.27)] and IL-10 [MSD = -0.13, 95%CI = (-0.31, 0.12)] levels. This indicates that the application of VitA in pediatric MPP also has the effect of reducing inflammatory response.
UNASSIGNED: Based on the meta-analysis results, VitA adjuvant therapy can significantly improve the clinical symptoms of pediatric MPP patients, shorten hospitalization time, promote the disappearance of lung rales, and alleviate cough and fever symptoms. In addition, VitA adjuvant therapy can effectively reduce inflammation levels, indicating its potential role in inhibiting inflammatory responses. In clinical practice, VitA adjuvant therapy for pediatric MPP can be promoted as a potential treatment option.
摘要：
■本研究的目的是通过荟萃分析评估维生素A（VitA）作为小儿肺炎支原体肺炎（MPP）辅助治疗的疗效，并研究其对炎症水平（IL-6，IL-10）的影响，为了探讨VitA在小儿MPP中的作用。
■采用系统的文献检索方法，搜索相关研究文献，根据预设的纳入和排除标准选择符合要求的RCT研究。然后，对纳入的文献进行了质量评价，并使用荟萃分析计算死亡率的综合效应值，住院,肺部啰音消失时间,咳嗽持续时间,发烧持续时间，IL-6和IL-10水平，并进行了异质性分析。IL-6和IL-10的水平代表儿科MPP患者的炎症水平，探索它们的变化对治疗的抗炎作用具有重要意义。
■共纳入10项RCT研究，总样本量1,485例,其中对照组750例,观察组735例。这项研究的荟萃分析结果表明，与不使用VitA的对照组相比，使用VitA辅助治疗的总临床疗效存在显着差异[OR=3.07，95CI=（2.81，4.27）]，P<0.05。然而,使用VitA作为辅助治疗与不使用VitA的对照组之间的不良反应率没有显着差异[OR=1.17，95CI=（0.61，2.27）]，P>0.05。同时,住院时间[MSD=-0.86,95%CI=(-1.61,-0.21)],肺部啰音消失时间[MSD=-0.78，95CI=（-1.19，-0.51）]，咳嗽持续时间[MSD=-1.07，95CI=(-1.41，-0.71)]，使用VitA作为辅助治疗的发热持续时间[MSD=-0.47,95CI=(-0.72,-0.23)]明显较低。此外,荟萃分析结果还显示,使用VitA辅助治疗可显著降低IL-6[MSD=-1.07,95CI=(-1.81,-0.27)]和IL-10[MSD=-0.13,95CI=(-0.31,0.12)]水平.这表明VitA在小儿MPP中的应用还具有减轻炎症反应的作用。
■根据荟萃分析结果，VitA辅助治疗可明显改善小儿MPP患者的临床症状,缩短住院时间,促进肺部啰音的消失，缓解咳嗽和发烧症状。此外,VitA辅助治疗能有效降低炎症水平，表明其在抑制炎症反应中的潜在作用。在临床实践中,VitA辅助治疗小儿MPP可作为一种潜在的治疗选择。
■采用系统的文献检索方法，搜索相关研究文献，根据预设的纳入和排除标准选择符合要求的RCT研究。然后，对纳入的文献进行了质量评价，并使用荟萃分析计算死亡率的综合效应值，住院,肺部啰音消失时间,咳嗽持续时间,发烧持续时间，IL-6和IL-10水平，并进行了异质性分析。IL-6和IL-10的水平代表儿科MPP患者的炎症水平，探索它们的变化对治疗的抗炎作用具有重要意义。
■共纳入10项RCT研究，总样本量1,485例,其中对照组750例,观察组735例。这项研究的荟萃分析结果表明，与不使用VitA的对照组相比，使用VitA辅助治疗的总临床疗效存在显着差异[OR=3.07，95CI=（2.81，4.27）]，P<0.05。然而,使用VitA作为辅助治疗与不使用VitA的对照组之间的不良反应率没有显着差异[OR=1.17，95CI=（0.61，2.27）]，P>0.05。同时,住院时间[MSD=-0.86,95%CI=(-1.61,-0.21)],肺部啰音消失时间[MSD=-0.78，95CI=（-1.19，-0.51）]，咳嗽持续时间[MSD=-1.07，95CI=(-1.41，-0.71)]，使用VitA作为辅助治疗的发热持续时间[MSD=-0.47,95CI=(-0.72,-0.23)]明显较低。此外,荟萃分析结果还显示,使用VitA辅助治疗可显著降低IL-6[MSD=-1.07,95CI=(-1.81,-0.27)]和IL-10[MSD=-0.13,95CI=(-0.31,0.12)]水平.这表明VitA在小儿MPP中的应用还具有减轻炎症反应的作用。
■根据荟萃分析结果，VitA辅助治疗可明显改善小儿MPP患者的临床症状,缩短住院时间,促进肺部啰音的消失，缓解咳嗽和发烧症状。此外,VitA辅助治疗能有效降低炎症水平，表明其在抑制炎症反应中的潜在作用。在临床实践中,VitA辅助治疗小儿MPP可作为一种潜在的治疗选择。
